Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Earnings for Verona Pharma plc (VRNA)
Earnings in 2023 (TTM): $-55,212,180
According to Verona Pharma plc's latest financial reports the company's current earnings (TTM) are $-55,212,180. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Verona Pharma plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-55,212,180 | $-54,369,000 |
| 2022 | $-68,448,000 | $-68,701,000 |
| 2021 | $-55,587,000 | $-55,569,000 |
| 2020 | $-65,000,000 | $-65,146,000 |
| 2019 | $-51,405,570 | $-41,879,950 |
| 2018 | $-30,622,526 | $-25,252,512 |
| 2017 | $-34,059,489 | $-27,699,772 |
| 2016 | $-7,369,003 | $-6,191,725 |
| 2015 | $-13,224,220 | $-10,987,967 |
| 2014 | $-5,856,673 | $-4,293,877 |
| 2013 | $-4,640,522 | $-4,163,303 |
| 2012 | $-4,145,331 | $-4,067,651 |
| 2011 | $-2,862,998 | $-2,670,476 |
| 2010 | $-2,913,940 | $-2,921,657 |
| 2009 | $-2,585,580 | $-2,585,580 |
| 2008 | $-1,966,699 | $-2,007,703 |
| 2007 | $-2,413,485 | $-2,413,485 |
| 2006 | $-1,191,199 | $-1,191,199 |
| 2005 | $44.74 K | $44.74 K |